Written Public Comments
Generation Patient regularly interacts with Congress and Federal agencies including the Food and Drug Administration, U.S. Patent and Trade Office, Department of Justice, and Department of Health and Human Services. Click the menu to the right to access our written public comments to drive policy change that benefits our young adult patient community.
-
Statement of Peyton Agard Miles on the ETHIC Act - June 4, 2026
Statement of Luis Gil Abinader on the ETHIC Act - June 4, 2026
Comment for the Record to Senate Judiciary: Pay-for-Delay, Patent Thickets, and Product Hopping - May 21, 2024
Open Letter to Congress: Young Adults Need Patent Reform, Not Just the IRA - October 10, 2023
Letter in support of S. 2780, the Medication Affordability and Patent Integrity Act - September 14, 2023
Letter to Senate HELP on User Fees: Young-Adult Age Brackets and Social Media Drug Ads - May 23, 2022
-
Comment to FDA - FDA oversight of AI companion tools and chatbots - August 13, 2026
Comment to FDA - MDUFA VI Draft Commitment Letter - August 7, 2026
Comment to FDA - Reauthorization of the Medical Device User Fee Amendments; Public Meeting - September 4, 2025
Comment to FDA - Reauthorization of the Prescription Drug User Fee Act; Public Meeting - August 19, 2025
Comment to FDA - Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies; Guidance for Industry - Sept 26, 2024
Comment to FDA - Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials - June 13, 2022
Comment on FDA's Study of Accelerated Approval Disclosures in Direct-to-Consumer Drug Ads - April 25, 2022
-
-
Generation Patient Comment on USPTO and FDA Public Listening Session - August 17, 2023
-